Spearheading Safe, Potent, & Scalable Innate Immune Therapies Spanning NK, iNKT, Gamma Delta, & Macrophages.
Realize Lasting Clinical Response with Next-Generation Engineering to Provide Off-the-Shelf Delivery for More Patients, Globally.
Driving Clinical Results with Allogeneic & Solid Tumor Innate Therapies
Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team, spanning preclinical development, clinical translation, CMC, process development, and clinical scale manufacturing, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies.
Download your copy of the Full Event Guide here.
Join over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies, gain regulatory know-how, optimize lymphodepletion and cryopreservation, and contrast cell sources for highly efficacious, scalable off-the-shelf therapies.
Promising brand-new speakers from new companies, interactive discussion, and engaging networking opportunities join the 8th Innate Killer Summit to forge new collaborations and realize the clinical potential of innate immune therapies.
70+ Industry-Leading Speakers Include:
Neil Sheppard
Director & Head of Research Technologies & Innovation T Cell Engineering Laboratory & Cellular Immunotherapies
University of Pennsylvania
Jeffrey Miller
Professor - Medicine Division Hematology & Transplantation Oncology
University of Minnesota
A Snapshot of this Year's Partners:
Lead Partner:
Industry Partner:
